IGI Logo

Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter December 31, 2024.

Consolidated Financial Highlights for nine month ended December 31, 2024:

Total revenue for 9MFY25 was at Rs.9,428 million as compared to Rs.10,923 million in 9MFY24; down 14% YoY.

EBITDA (incl. other income) was at Rs.2,624 million in 9MFY25 as compared to Rs.3,062 million in 9MFY24, this would translate into 28% EBITDA margin in 9MFY25.

Profit After Tax was at Rs.970 million in 9MFY25 as compared to Rs.1,270 million in 9MFY24.

Consolidated Financial Highlights for Quarter ended December 31, 2024:

Total revenue for Q3FY25 was at Rs.3,866 million as compared to Rs.2,979 million in Q3FY24; up 30% YoY.

 EBITDA (incl. other income) was at Rs.1,208 million in Q3FY25 as compared to Rs.815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter.

 Profit After Tax was at Rs.542 million in Q3FY25 as compared to Rs.260 million in Q3FY24; up 108% YoY.

Speaking on the performance, Mr Anand Desai, Managing Director, Anupam Rasayan commented, “Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market."

"With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26."

Above views are of the author and not of the website kindly read disclaimer